Drug Profile
Coleneuramide
Alternative Names: MCC-257Latest Information Update: 09 Aug 2010
Price :
$50
*
At a glance
- Originator Mitsubishi Pharma Corporation
- Developer Mitsubishi Tanabe Pharma Corporation
- Class Analgesics
- Mechanism of Action Nerve growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic neuropathies
Most Recent Events
- 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku Co. Ltd to form Mitsubishi Tanabe Pharma Corporation
- 11 May 2006 Phase-II clinical trials in Diabetic neuropathies in USA (PO)
- 06 Aug 2003 No development reported - Preclinical for Diabetic neuropathies in Japan (PO)